Small Trial Shows Big Risks of Giving First Line Pembrolizumab to EGFR Mutation-Positive Patients, Even with High Tumor PD-L1 Expression (BMIC-042) - 102204

Spotlight
Video

Small Trial Shows Big Risks of Giving First Line Pembrolizumab to EGFR Mutation-Positive Patients, Even with High Tumor PD-L1 Expression (BMIC-042)

BeaconMedIC has 67 videos Subscribe Here

Loading........
Description: Dr. Jack West summarizes a small trial from UCLA that tests the utility of giving first line immunotherapy to EGFR mutation-positive patients with high tumor PD-L1 expression, which led to poor outcomes that should cast a long shadow on this approach.
Shared By : BeaconMedIC
Posted on : 06/27/18
Added : 5 months ago
Category : Immunotherapy